

SWIXX SIGNS NEW ADDENDUM WITH JAZZ; ADDS VYXEOS® LIPOSOMAL FOR POLAND

SWIXX ANNOUNCEMENT NO. 42

December 3rd, 2021

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland announced today the extension of its existing exclusive distribution contract on Vyxeos® Liposomal with Jazz Pharmaceuticals Ireland Limited of Dublin, a fully-owned subsidiary of Jazz Pharmaceuticals plc. Earlier this year, Jazz had appointed Swixx as exclusive distributor to import, use, market, sell and distribute Vyxeos® Liposomal 44mg/100mg powder for concentrate for solution for infusion in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Romania, Slovakia, and Slovenia. The new amendment extends the Vyxeos® Liposomal territory to Poland.

Vyxeos® Liposomal is a dual-drug liposomal formulation of daunorubicin and cytarabine that is indicated in the EU for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).¹ Vyxeos® Liposomal is the first chemotherapy in over 40 years to demonstrate a significant overall survival advantage versus the current conventional treatment, 7+3 chemotherapy (cytarabine/daunorubicin), in a Phase 3 study of adult patients, with newly diagnosed high-risk/secondary AML.²

“It’s a great pleasure to see our cooperation with Jazz on Vyxeos® liposomal extended to Poland and support of Jazz when needed in other therapy areas” commented Swixx COO, Dr. Dezso Martha. “Our goal is to work with Jazz, governments and the broad CEE healthcare community to make this therapy more widely available to our CEE patients. We are honoured that Jazz has afforded us this opportunity to work with this important medicine in Poland.

“I am also delighted to report,” Dr. Martha continued, “that both members of Jazz’s growing Polish organization, Malgorzata Boguszewska and Patrycja Ortyl-Siekańska, are joining Swixx Poland. Please allow me to warmly welcome them to Swixx. It will be a privilege for us to work with such professionals – we value this opportunity to inject Jazz expertise into our Polish team and to provide continuity to patients and healthcare partners in Poland.”

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe and Russia. With 600 employees and sales likely to exceed 270M Euros in 2021, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

Note on Unsubscribing from Swixx Announcement Mailing List: In accordance with the European Union's GDPR (General Data Protection Regulation) provisos, should you wish to unsubscribe / opt out of our mailing list, please send to Maja.Boskovic@swixxbiopharma.com a one-line message "Please unsubscribe me."

¹ Vyxeos Liposomal Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/9442/smpc>; last accessed: November 2021.

² Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684-2692.